CA Gov
Through the Canadian Institutes of Health Research Clinical Trials Fund, the Government of Canada is investing $43.1M in 14 new clinical trials projects.
The Clinical Trials Fund, a key component of Canada's Biomanufacturing and Life Sciences Strategy, was established in 2022 to reinforce Canada's clinical trials environment through three funding streams:
- a pan-Canadian Clinical Trials Consortium to advance coordination of clinical trials conducted in Canada;
- Clinical Trials Training Platforms to recruit, train and mentor the next generation of clinical trials researchers and health care workers; and
- Clinical Trials Projects to support a variety of clinical trials phases and designs.
These 14 new trials represent the second round of funding through the Clinical Trials Fund and Canada's Strategy for Patient-Oriented Research. The first round of investments supported 22 clinical trials beginning in 2022, alongside investments in the creation of a clinical trials consortium and seven training platforms.
| Nominated Principal Investigator | Institution | Project title |
|---|---|---|
| Dr. Angela M. Cheung | University Health Network (Toronto, Ontario) | A Randomized Phase 2 Dose Ranging, Active Control Trial of Using a Sequential Rebreathing Oxygen Mask (Hi-OxSR) to Increase PCO2 for the Treatment of Post COVID Cognitive Dysfunction (RECLAIM-Hi-OxSR) |
| Dr. Scott A. Halperin | Dalhousie University (Halifax, Nova Scotia) |
Open-label, phase 1/2, dose-escalation and dose-confirmation clinical trial to establish a Controlled Human Infection Model (CHIM) by determining and confirming the optimal, safe, and reproducible Influenza A:H3N2 dose administered intranasally to healthy adults 18-40 years of age that induces mild symptomatic infection and detection of Influenza A:H3N2 in nasal secretions by culture and/or PCR |
| Dr. Patrick R. Lawler | Research Institute of the McGill University Health Centre (Montreal, Quebec) |
CLEAR-HORIZONS Post-Sepsis Platform Trial: Statin Pilot RCT |
| Dr. Vanessa Meier-Stephenson | University of Alberta (Edmonton, Alberta) |
Phase 1 randomized, double-blinded, placebo-controlled clinical trial of an adjuvanted protein-based Hepatitis C Virus (HCV) vaccine candidate |
| Dr. Bijoy K. Menon | University of Calgary (Calgary, Alberta) |
A Multicentre, Randomized, Double-blinded, Placebo-controlled, Parallel Group, Single-dose Design to Determine the Efficacy and Safety of NoNO-42 in Participants with Acute Ischemic Stroke Selected for Thrombolysis |
| Dr. Richard Menzies | Research Institute of the McGill University Health Centre (Montreal, Quebec) |
Finding the right balance: An adaptive trial to identify the safest regimen with the shortest duration for TB prevention (treatment of TB Infection) |
| Dr. John Muscedere | Queen's University (Kingston, Ontario) | Furosemide as Supportive Therapy for Respiratory Failure secondary to Pulmonary Infection (FAST - 3) |
| Dr. Lawrence P. Richer | University of Alberta (Edmonton, Alberta) |
Taurine Supplementation as a Novel Therapeutic Approach for Neurocognitive Symptoms in the REcovering From COVID-19 Lingering Symptoms Adaptive Integrative Medicine (RECLAIM) Platform Trial |
| Dr. Sean B. Rourke | Unity Health Toronto (Toronto, Ontario) |
"Test and Treat" Clinical Trial Intervention to Evaluate the Performance and Treatment Outcomes of Novel Point-of-Care and Self-Test Versions of a Rapid Combination Treponemal/non-Treponemal Antibody Test |
| Dr. Ruth Sapir-Pichhadze | Research Institute of the McGill University Health Centre (Montreal, Quebec) |
Immunogenicity and safety of COVID-19 vaccine Co-administration and Interval in Immunocompromised hosts (CO2I2 Trial) |
| Dr. Makeda Semret | Research Institute of the McGill University Health Centre (Montreal, Quebec) |
Biomarker Signature-supported Antibiotic Treatment Decisions in ICU (BAST-ICU) |
| Dr. Bernard Thebaud | Ottawa Hospital Research Institute (Ottawa, Ontario) |
Helping Underdeveloped Lungs with Cells (HULC-2) - A Randomized Controlled Trial to test the efficacy of umbilical cord-derived mesenchymal stromal cells (UC-MSC) in reducing respiratory morbidity in preterm infants at risk of bronchopulmonary dysplasia (BPD) |
| Dr. Jagdeep S. Walia | Queen's University (Kingston, Ontario) | A Phase 1/2, Open-Label Clinical Study to Evaluate the Safety and Efficacy of Intrathecal hB-A Gene Therapy for Treatment of Infantile Onset GM2 Gangliosidosis |
| Dr. Ryan Zarychanski | University of Manitoba (Winnipeg, Manitoba) |
Dexamethasone For Preventing Deterioration In Community Acquired Pneumonia (DEFEND-CAP) |
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
